Related Editorial
Since its first successful use nearly 30 years ago, gene therapy has grown into an important if experimental part of the medical sector. Now it is taking off in a big way, offering treatment for chronic ailments such as diabetes and other conditions. PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (PRVCF Profile) is at the forefront of this segment of healthcare, seeking preventive gene treatments to tackle Type 2 diabetes. MannKind Corp. (NASDAQ: MNKD) is offering other innovations for diabetics, with the first inhalation-based drug for managing insulin levels, and Danish multinational Novo Nordisk (NYSE: NVO) offers support for tackling diabetes, with 85% of its business in this area. The potential of gene therapy is being proved with other ailments, for example the work of Sangamo Therapeutics, Inc. (NASDAQ: SGMO) on hemophilia, Huntington’s disease, and HIV. Even obscure diseases are becoming treatable through gene therapy thanks to Audentes Therapeutics, Inc. (NASDAQ: BOLD), whose virally carried treatments tackle Criger-Najjar syndrome and Pompe disease.
To view the full editorial, visit http://nnw.fm/Xj13T
